Clinical Trial Update: A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study of XL844 alone and in combination with gemcitabine in adults with advanced cancers was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Lymphoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• XL844

Snippet

Sponsor: Exelixis | Conditions: Cancer, Lymphoma | Phase 1 | Status: TERMINATED